Biotechnology company focusing on developing diagnostics and psilocybin based therapeutics for chronic and mental conditions Nova Mentis Life Science Corp. (CSE: NOVA) (OTCQB: NMLSF) announced having appointed Dr. Stephen Glazer as a director and the chief science officer of the company.
This announcement was made by the company’s president and chief executive officer, Will Rascan who acknowledged Glazer brings with him thirty years of experience in the medical field.
“We’re proud to welcome Dr. Glazer to our team, as he brings passion, dedication and 30 years of medical experience to our Board. He is a national leader in his field and his quest to help patients with chronic conditions with unmet medical needs will be an asset to our company and the research underway,” said the CEO.
Dr. Glazer is a specialist in bariatric, a branch of medicines which involves studying and treating patients living with obesity. He started his medical career in Toronto at North York Branson Hospital over two and half decades ago. He is currently the president of the Canadian Association of Bariatric Physicians and Surgeons.
“I’m looking forward to working closely with the team to help advance their clinical research program for neuroinflammatory disorders. Their novel approach, which includes using leading-edge AI technologies to accelerate the discovery of new therapeutics, is aligned with my scientific and medical interests, and I’m excited to add my expertise to the program,” said Dr. Glazer.
